Drug Profile
Research programme: small molecule therapeutics - OncoEthix
Alternative Names: OTX009Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator OncoEthix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 18 Dec 2014 OncoEthix has been acquired by Merck & Co
- 20 Nov 2012 Early research in Cancer in USA (unspecified route)